Caribou Biosciences Inc (CRBU) 옵션

What do you think of their shift to partial HLA matching?

CRBU. Under $2

CRBU under $2

CRBU READY TO BEAST

CRBU...NEW SCAN JUST GAVE ME THIS BIO

CRBU under $3

CRBU under $2

CRBU under $3

CRBU under $3

Earlier this year development of the lead CAR-NK programme, CB-020, was stopped, and now they are out of CAR-NK altogether. They disclosed it in an SEC filing and outlined a 12% workforce reduction https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/crbu-20240716.htm

This should extend their cash runway by at least six months, into the second half of 2026.

CRBU under $3

CRBU new 52 week low

CRBU new 52 week low

Without engaging macrophage long term, CART and other ACT will have persistence issue as regulatory lymphocytes and TAM recoup. AFMD has the best approach with ICE engaging a few B CBNK cells for start and engaging endogenous NK and M in the maintenance phase

Any good news in here comming?

Among patients with four or more matching HLA alleles, mPFS was 14.4 months, versus 2.8 months in patients with three or fewer matches. But this is based on a retrospective analysis, so they will need to prove the theory prospectively. It was better in LBCL, with mPFS not reached, versus 2.8 months. Also, some improvement in the now-selected dose, 80 million CAR-T cells.

The BCMA-targeted space is already crowded enough and off-target toxicities, including agranulocytosis* could be a problem for its anti-CLL-1 CAR.

* CLL-1 is also highly expressed on almost all granulocytes and monocytes and on parts of myeloid progenitors in the normal bone marrow and peripheral blood.

CRBU new 52 week low

Yep, not a positive trend hence sub $3’s…fortunately other trials for varied indications could save company…

It gets worse. The updated (CB-010) data shows that the ORR (including CR rate) has fallen, so has the mDOR, the six-month PFS is poor and the pivotal trial has been delayed until H2 2025 following a new HLA partial matching strategy. The latter completely alters (in a bad way) the commercial strategy for an allo CAR-T product. They now need thirteen different off-the-shelf batches to be able to cater to ~90% of patients based on an ideal HLA match.

CRBU new 52 week low

CRBU new 52 week low

CRBU under $5

It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???

CRBU new 52 week low

Yes, with both drugs still in development. As for CRBU, they gave an update (plus public offering) https://finance.yahoo.com/news/caribou-biosciences-reports-positive-clinical-200100822.html https://investor.cariboubio.com/static-files/d818ed1a-aea2-41c1-84ea-bd05a4276cbb

Personally, there seem to be red flags, such as no expansion/persistence data. I know they give huge amounts of LD chemo, higher (I think) than anyone else, which could be generating responses, explaining why there is no dose response.

.

$23.00 price target! Now that is a good start!! Glad I loaded up! Jmo

Didn't they buy TRIL? Just gambling with billions from US government.

PFE is very selective in who they fund https://finance.yahoo.com/news/caribou-biosciences-announces-25-million-120000433.html

Great day in my accounts again! Really liking my CRBU shares! Jmo holding for the long haul!!

CRBU now No 9 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Added to my existing shares today, I bought shares months ago. I like Crbu a crisper company! Looks like Pfizer does also! Jmo

CRBU Loss 108 Million Dollars Company only has preclinical and phase 1 in its pipeline company is Years away from having anything if ever did a stock offering at 5.33$ for 25 Million thats only 1 QTR Cash burn for this company Sell the News https://www.cariboubio.com/pipeline/

CRBU= JUST WOW

https://finviz.com/quote.ashx?t=CRBU&ty=c&ta=1&p=d

CRBU No 1 on the early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc